Cometriq cabozantinib: Additional Phase III data

Data from a subgroup analysis of 215 patients with determined Ret proto-oncogene (RET) status from the double-blind, international Phase III EXAM trial in 330 patients with locally advanced or metastatic MTC showed that once-daily cabozantinib significantly improved median PFS in patients with a RET mutation vs. patients with RET wild-type (60 vs. 25 weeks, p=0.0001). Cabozantinib also significantly improved median PFS in patients with RET M918T mutation vs. patients with any other RET mutation (61 vs. 26 weeks, p=0.009). A post hoc analysis showed that Ras mutation-positive patients had similar tumor response rates (31% vs. 32%) and PFS (47 vs. 60 weeks) vs. RET mutation-positive patients. Data were presented at the American Society of Clinical Oncology meeting. ...